Normand E. Allaire

Normand E. Allaire

Auto-generated profile, based on publicly available information

Normand E. Allaire

CFFT Lab, Cystic Fibrosis Foundation, Lexington, MA 02421, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
KHKate L. Henry
Kate L. Henry
DKDebra Kellner
Debra Kellner
BBBekim Bajrami
Bekim Bajrami
JAJohn E. Anderson
John E. Anderson
MBMercedes Beyna
Mercedes Beyna
MOMichelle L. Ols
Michelle L. Ols
Members of the family of nuclear factor κB (NF-κB) transcription factors are critical for multiple cellular processes, including regulating innate and adaptive immune responses, cell proliferation, and cell survival. Canonical NF-κB complexes are retained in the cytoplasm by the inhibitory protein IκBα, whereas noncanonical NF-κB complexes are retained by p100. Although activation of canonical NF-κB signaling through the IκBα kinase complex is well studied, few regulators of the NF-κB–inducing kinase (NIK)–dependent processing of noncanonical p100 to p52 and the subsequent nuclear translocation of p52 have been identified. We discovered a role for cyclin-dependent kinase 12 (CDK12) in transcriptionally regulating the noncanonical NF-κB pathway. High-content phenotypic screening identified the compound 919278 as a specific inhibitor of the lymphotoxin β receptor (LTβR), and tumor necrosis factor (TNF) receptor superfamily member 12A (FN14)–dependent nuclear translocation of p52, but not of the TNF-α receptor–mediated nuclear translocation of p65. Chemoproteomics identified CDK12 as the target of 919278. CDK12 inhibition by 919278, the CDK inhibitor THZ1, or siRNA-mediated knockdown resulted in similar global transcriptional changes and prevented the LTβR- and FN14-dependent expression of MAP3K14 (which encodes NIK) as well as NIK accumulation by reducing phosphorylation of the carboxyl-terminal domain of RNA polymerase II. By coupling a phenotypic screen with chemoproteomics, we identified a pathway for the activation of the noncanonical NF-κB pathway that could serve as a therapeutic target in autoimmunity and cancer.

17 January 2023 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
NANormand E. Allaire
Normand E. Allaire
UGUta Griesenbach
Uta Griesenbach
K Batsheva Kerem
Batsheva Kerem
JLJohn D. Lueck
John D. Lueck
NSNoemie Stanleigh
Noemie Stanleigh
YOYifat S. Oren
Yifat S. Oren

11 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
HBHermann Bihler
Hermann Bihler
ASAndrey Sivachenko
Andrey Sivachenko
LMLinda Millen
Linda Millen
PBPriyanka Bhatt
Priyanka Bhatt
APAmita Thakerar Patel
Amita Thakerar Patel
MMMartin Mense
Martin Mense
Background: In 2017, the US Food and Drug Administration initiated expansion of drug labels for the treatment of cystic fibrosis (CF) to include CF transmembrane conductance regulator (CFTR) gene variants based on in vitro functional studies. This study aims to identify CFTR variants that result in increased chloride (Cl - ) transport function by the CFTR protein after treatment with the CFTR-modulator combination elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA). These data may benefit people with CF (pwCF) who are not currently eligible for modulator therapies. Methods: Plasmid DNA encoding 655 CFTR variants and wild-type (WT) CFTR were transfected into Fisher Rat Thyroid cells that do not natively express CFTR. After 24 hours of incubation with control or TEZ and ELX, and acute addition of IVA, CFTR function was assessed using the transepithelial current clamp conductance assay. Each variant’s baseline activity, responsiveness to IVA alone, and responsiveness to the TEZ/ELX/IVA combination were measured in three different laboratories. Western blots were conducted to evaluate CFTR protein maturation and complement the functional data. Results and Conclusions: 253 variants not currently approved for CFTR modulator therapy showed low baseline activity (<10% of normal CFTR Cl - transport activity). For 152 of these variants, treatment with ELX/TEZ/IVA improved the Cl - transport activity by ≥10% of normal CFTR function, which is suggestive of clinical benefit. ELX/TEZ/IVA increased CFTR function by ≥10 percentage points for an additional 140 unapproved variants with ≥10% but <50% of normal CFTR function at baseline. These findings significantly expand the number of rare CFTR variants for which ELX/TEZ/IVA treatment should result in clinical benefit.

11 September 2026 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
HBHermann Bihler
Hermann Bihler
ASAndrey Sivachenko
Andrey Sivachenko
PBPriyanka Bhatt
Priyanka Bhatt
ABAshley Baldwin
Ashley Baldwin
JHJan Harrington
Jan Harrington
MMMartin Mense
Martin Mense

3 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NANormand E. Allaire
Normand E. Allaire
MAMathew Armstrong
Mathew Armstrong
JYJae Seok Yoon
Jae Seok Yoon
PBPriyanka Bhatt
Priyanka Bhatt
JHJan Harrington
Jan Harrington
CCCalvin Cotton
Calvin Cotton
Background: Nonsense or Premature Termination Codon (PTC) mutations of the CFTR gene are pathogenic and found in ∼10% of North American people with cystic fibrosis. PTC mutations induce Nonsense-Mediated mRNA Decay (NMD), leading to a substantial (∼80-90%) reduction in full-length mRNA. This reduction is a key contributor to PTC mutation-related pathology. Various approaches to evade NMD and preserve the impacted mRNA transcript have been explored but have not progressed to clinical development, leaving NMD a significant hurdle for PTC readthrough therapy. Methods: Antisense oligonucleotides (ASOs) were tiled across intron 22 splice donor (SD) and acceptor (SA) sites of the CFTR gene. Immortalized airway cells were treated with SD and SA ASOs, and those yielding the greatest increase in a CFTR NMD-insensitive mRNA isoform (e22 trunc mRNA) were tested in combinations. Top SD/SA ASO pairs were assessed for their impact on e22 trunc mRNA via ddPCR, e22 trunc protein via western blot, and CFTR-mediated chloride (Cl - ) transport via transepithelial electrophysiological measurements in immortalized and primary human bronchial epithelial (hBE) cell cultures. Results: We demonstrate that e22 trunc mRNA generates a truncated CFTR protein whose Cl - transport function can be enhanced with elexacaftor/tezacaftor/ivacaftor (ETI) treatment. ASO and ETI treatment in combination restore ∼20% and 25% of wild-type CFTR Cl - transport function in immortalized epithelial and primary hBE cells homozygous for CFTR W1282X, respectively. Conclusions: This study lays the groundwork for advancing ASO-mediated upregulation of e22 trunc mRNA and protein as a therapeutic approach for cystic fibrosis caused by 3’-terminal CFTR PTC mutations.

2 January 2026 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
NANormand E. Allaire
Normand E. Allaire
MAMatthew S. Armstrong
Matthew S. Armstrong
JYJae Seok Yoon
Jae Seok Yoon
MWMercy C. Walker
Mercy C. Walker
PBPriyanka Bhatt
Priyanka Bhatt
MMMartin Mense
Martin Mense
Nonsense or premature termination codon (PTC) variants of the CFTR gene are pathogenic and found in ∼10% of North American people with cystic fibrosis. In addition to encoding incomplete proteins, PTC variants induce nonsense-mediated mRNA decay (NMD), leading to ∼80%–90% reduction in full-length mRNA. This reduction is a contributor to PTC mutation-related pathology. E22 trunc is a naturally occurring truncated CFTR mRNA that terminates before the W1282X PTC variant and is resistant to NMD. To induce its expression, antisense oligonucleotides (ASOs) were tiled across intron 22 splice donor (SD) and splice acceptor (SA) sites. Top SD/SA ASO pairs were assessed for their impact on e22 trunc mRNA, e22 trunc protein, and CFTR-mediated chloride (Cl−) transport in immortalized and primary human bronchial epithelial (hBE) cell cultures. We demonstrate that e22 trunc mRNA generates a truncated CFTR protein whose Cl− transport function can be enhanced with elexacaftor/tezacaftor/ivacaftor (ETI) treatment. ASO and ETI treatment in combination restore ∼20% and 25% of wild-type CFTR Cl− transport function in immortalized epithelial and primary hBE cells homozygous for CFTR W1282X, respectively. This study provides a foundation for advancing ASO-mediated upregulation of e22 trunc mRNA and protein as a therapeutic approach for cystic fibrosis caused by 3′-terminal CFTR PTC mutations.